Back to all studies
Not Yet RecruitingACTRN12623000423617

Safety study of Safety, Pharmacokinetics, and Pharmacodynamics of Lucid-201 in depression

This study is not yet recruiting in Australia. It is testing Safety, Pharmacokinetics, and Pharmacodynamics of Lucid-201 for depression.

Depression, Mental healthDrugFrom 18 Years to 60 Years

The public registry lists this study as not yet recruiting. Check the official record and ask the research team when recruitment may open.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

In plain English

Key information made simple

What the source says

The registry describes this research topic: “LUCID-201-001: A Double-Blind, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Lucid-201 in Healthy Male and Female Volunteers and Patients with Depressive Symptoms on a selective-serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI)”. This is an interventional study. The registry lists a target sample size of 48. Recruitment status at the registry update of 2024-05-29: not yet recruiting. Read the original description and eligibility criteria, and confirm the practical details with the study team.

What should you check before joining?

Check the full criteria in the official source. Ask the team to confirm recruitment, locations, visits, risks and participation requirements.

Your next step

Check the study details

Check the official source, then confirm these points with the research team.

View official study record (opens in a new tab)

  • Recruitment and eligibility

    Is a site open, and who can take part?

  • Visits and time

    Where are visits, can any be remote, and how much time is needed?

  • Costs and support

    What costs, reimbursement or compensation apply?

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateJuly 1, 2024
Recruitment status
Not Yet Recruiting
Enrollment listed in the registry
48
Sponsor
FSD Pharma Australia Pty Ltd
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
Australia
Age range
From 18 Years to 60 Years
Official registry ID
ACTRN12623000423617
Official title
A Double-Blind, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Lucid-201 in Healthy Male and Female Volunteers and Patients with Depressive Symptoms on a selective-serotonin reuptake inhibitor (SSRI) or a serotonin-norepinephrine reuptake inhibitor (SNRI)

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: ACTRN12623000423617. We help you review the study, but cannot decide medical eligibility.

Check recruitment and locations

Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.

View official study record (opens in a new tab)

The overall study status can differ from each site's status. Open a country to see its locations and their registry status.

Australia · 2 sites
  • Nucleus Network
    Melbourne
    Site status: Not listed — confirm with the team
  • Nucleus Network
    Geelong
    Site status: Not listed — confirm with the team
In practice

For you

Participation may contribute to research. Personal benefit is not guaranteed.

Ask the research team to explain the activities, time commitment, and follow-up involved.

Study sites are listed. Confirm the relevant site and any travel before making plans.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve a medication?

This appears to be a medication / drug study. Phase 1 studies usually focus mainly on safety, tolerability, dosage, and side effects. They often involve healthy volunteers, but not always. Some Phase 1 studies include people living with the target condition.

Who might this study be for?

This study may concern people with depression; age range: From 18 Years to 60 Years. The criteria appear strict, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

What would I likely need to do?

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

Will I need to change, stop, or stabilize my current treatment?

The public registry appears to mention rules about current treatment, stability, stopping treatment, or dose changes. Do not change your treatment for a study without medical guidance. Ask the study team and your clinician what is required, what is not allowed, and how safety is monitored.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by FSD Pharma Australia Pty Ltd, which appears to be a pharmaceutical company. The listed contact or investigator is Philip Ryan. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The public registry lists this study as not yet recruiting. Check the official record and ask the research team when recruitment may open.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.